p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer

Area of Science:

• Oncology
• Genetics
• Urology

Background:

• The tumor suppressor gene p53 and its effector p21 are crucial in human malignancy development.
• Polymorphisms in p53 codon 72 and p21 codon 31 have been linked to cancer susceptibility.
• Limited research exists on their specific impact on prostate cancer risk.

Purpose of the Study:

• To investigate the association between p53 codon 72 and p21 codon 31 polymorphisms and prostate cancer risk.
• To analyze the relationship between these polymorphisms and benign prostatic hyperplasia (BPH).
• To examine potential associations in a Taiwanese population.

Main Methods:

• A case-control study involving 200 prostate cancer patients, 247 age-matched controls, and 181 symptomatic BPH patients.
• Genotyping was performed for p53 codon 72 and p21 codon 31 polymorphisms.
• Statistical analysis was conducted to determine risk associations, adjusting for covariates.

Main Results:

• No significant association was found between p53 polymorphism and prostate cancer risk.
• The p21 Arg/Arg genotype showed a 1.78-fold increased risk of prostate cancer compared to the Ser/Ser genotype.
• This association was stronger in younger men, localized disease stages, and moderately differentiated cancers.
• The p21 Arg/Arg genotype was also linked to BPH risk in men with large prostate volumes.

Conclusions:

• The p21 codon 31 polymorphism, particularly the Arg/Arg genotype, may be associated with an increased risk of prostate cancer.
• This genetic variant might also play a role in the development of prostate enlargement and BPH.
• Further research is warranted to elucidate the precise mechanisms involved.